Shandong Xinhua Pharmaceutical Company Limited

Research Shandong Xinhua Pharmaceutical Company Limited (XIN) on Bullrun: valuation model: 28.1% undervalued, market cap EUR 989.07M, P/E 12.5, dividend yield 10.0%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

Bullrun's latest valuation model marks Shandong Xinhua Pharmaceutical Company Limited as 28.1% undervalued; latest market cap is EUR 989.07M; P/E is 12.5; dividend yield is 10.0%.

About Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics.

Frequently asked questions

Is Shandong Xinhua Pharmaceutical Company Limited overvalued or undervalued?

Bullrun's valuation model currently marks Shandong Xinhua Pharmaceutical Company Limited as 28.1% undervalued.

What is Shandong Xinhua Pharmaceutical Company Limited's market cap?

Shandong Xinhua Pharmaceutical Company Limited's market capitalization is EUR 989.07M.

What is Shandong Xinhua Pharmaceutical Company Limited's P/E ratio?

Shandong Xinhua Pharmaceutical Company Limited's price-to-earnings (P/E) ratio is 12.5.

Does Shandong Xinhua Pharmaceutical Company Limited pay a dividend?

Shandong Xinhua Pharmaceutical Company Limited has a dividend yield of 10.0%.

What does Shandong Xinhua Pharmaceutical Company Limited do?

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally.